JohnPerentesisMDFAAP

Pediatric Hematology & Oncology • Cincinnati, OH

Pediatric Hematologic Oncology

Professor & Cancer/Blood Institute Director, Director of Oncology & Cancer Programs, Kleisinger Chair for New Cancer Treatments, Cincinnati Children's Hospital, University of Cincinnati College of Medicine

Join to view full profile

Dr. Perentesis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Perentesis' full profile

Already have an account?

Office
3333 Burnet Avenue
MLC 7018; Loc T7.200
Cincinnati, OH 45229
Phone+1 513-636-4266

Fax+1 513-636-3549

Summary

Our mission is to use disruptive innovation to cure cancer in children and young adults, and assure survivors longevity with wellness. We're proud to be ranked as the #1 children's cancer program in the nation by US News.

Our strategic plan targets: (1) Next generation precision medicine and new drug design/discovery/development, (2) New immune and cellular engineering therapies, and (3) Advanced radiation/proton therapies.

Our work led to the recent FDA pediatric approvals for Selumetinib and Vyxeos/CPX-351, and we performed the first in human clinical trial of ultrahigh dose rate FLASH proton therapy for cancer.

I'm Co-Director of the Cancer & Blood Disease Institute, and the Chief of Oncology and Proton Therapy Programs at Cincinnati Children's Hospital. We are a 102-bed dedicated pediatric/young adult cancer center within a 650 bed academic children's hospital spanning two campuses. Cincinnati Children’s is an international referral center for relapse and high-risk cancer care and stem cell transplant. The Cincinnati Children’s Cancer/Blood Institute has ~ 1,000 employees and over 100 MD, PhD and MD/PhD board-certified and research faculty organized in “team science” clinical/translational specialty programs in leukemias/lymphomas and marrow failure, brain tumors, neuroblastoma, musculoskeletal and NF/neural tumors, liver tumors, renal tumors, testicular/ovarian tumors, novel radiation therapy approaches, vascular tumors, and cancer survivorship.

Education & Training

University of Minnesota Medical SchoolPostdoctoral, Biochemistry/Oncology, 1986 - 1990
University of MinnesotaFellowship, Pediatric Hematology/Oncology, 1983 - 1986
University of MinnesotaResidency, Pediatrics, 1980 - 1983
University of Michigan Medical SchoolClass of 1980

Certifications & Licensure

OH State Medical License 2003 - 2026
MN State Medical License 1991 - 2007
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Start of enrollment: 1998 Nov 01
Terminated
Phase 1
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2005 Oct 01
Completed
Phase 1
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas Start of enrollment: 2010 Jul 10
Completed
Phase 2
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2012 Sep 01
Completed
Phase 2
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Sep 17
Completed
Phase 1
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Start of enrollment: 2013 Jun 24
Completed
Phase 2
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Registry for Proton Beam Radiation Therapy Start of enrollment: 2013 Dec 18
Completed
Roles: Contact, Principal Investigator
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Start of enrollment: 2018 Dec 27
Recruiting
Phase 1
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Start of enrollment: 2013 Sep 01
Completed
Phase 1
FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax Start of enrollment: 2023 Mar 08
Recruiting
Not Applicable
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy Start of enrollment: 2012 Jul 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis.
Ashley E Culver-Cochran, Aishlin Hassan, Kathleen Hueneman, Kwangmin Choi, Averil Ma
Nature Communications. 2024-10-24
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukae...
Francis R LeBlanc, Erin H Breese, Karen C Burns, Ellen K Chang, LaQuita M Jones
British Journal of Haematology. 2024-09-01
Evolution of Proton Radiation Therapy Brainstem Constraints on the Pediatric Proton/Photon Consortium Registry.
Dora Correia, Daniel J Indelicato, Arnold C Paulino, Ralph Ermoian, Stephen Mihalcik
Practical Radiation Oncology. 2024-08-10

Journal Articles

Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.
Freyer DR, Felgenhauer J, Perentesis J; COG Adolescent and Young Adult Oncology Discipline Committee., Pediatr Blood Cancer, 6/1/2013
Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.
Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S; COG Acute Myeloid Leukemia Committee., Pediatr Blood Cancer, 6/1/2013

Lectures

Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

FLASH Proton Therapy Clinical Trial Begins on Cancers Involving Bones in the ChestMarch 28th, 2023
Varian and the Cincinnati Children's/University of Cincinnati Medical Center Proton Therapy Center Announce Promising Results from FAST-01, First-in-Human Clinical Trial of Flash TherapyOctober 24th, 2022
Small Molecule Targets Achilles' Heel of AML, Kills Cancer CellsMarch 16th, 2022
Join now to see all

Grant Support

Molecular Studies Of DOWN Syndrome LeukemiaNational Cancer Institute2005–2008
Genetic Engineering Of Targeted TherapiesNational Cancer Institute1994–1997
Genetic Engineering Of Therapies For Myeloid LeukemiaNational Cancer Institute1993
Molecular Study Of Ribosomal Toxins And ApplicationsNational Institute Of Allergy And Infectious Diseases1987–1991